Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 8Uterine Cervical Neoplasms 4Stomach Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Advanced Solid Tumors 4Lung Neoplasms 3Carcinoma, Renal Cell 3Urinary Bladder Neoplasms 2Solid Tumor 2Ovarian Neoplasms 2Neoplasms 2Melanoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor, Unspecified, Adult 1Recurrence 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Multiple Myeloma 1Metastatic Urothelial Cancer 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Kidney Neoplasms 1Erythrocytosis, Familial, 4 1Endometrial Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Dexamethasone 64Lenalidomide 34pomalidomide 33Cyclophosphamide 33Rituximab 31Bortezomib 29venetoclax 27fludarabine 26Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 16Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Injections 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × zimberelimab × Clear all
NCT05798819 2023-04-05

A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer

Guangzhou Gloria Biosciences Co., Ltd.

Phase 3 Not yet recruiting
424 enrolled

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡